Moglix Raises $120M in Series B; Valued at $1 Billion
18 May, 2021
– Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding.
– The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team.
– The company intends to use the funds to accelerate growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.